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Background:  Periprocedural  management  of antiplatelet  or  anticoagulant  therapy  at  the  time  of  device
implantation  remains  controversial.
Methods: We  reviewed  all cases  for whom  a pacemaker  was  implanted  in  our  institution  between  January
2008  and June  2009.  In addition,  beginning  in  June  2009,  we  prospectively  collected  data  from  all  patients
admitted  to our  institution,  for whom  a pacemaker  was  placed.  Clinical  characteristics  and  anticoagu-
lant/antiplatelet  drug  use were  evaluated.
Results: A  total  of  574  patients  underwent  a permanent  pacemaker  implantation.  Of  these,  20 patients
(3.6%,  9 women)  experienced  a hematoma  on pacemaker  pocket  site.  Patients  were  aged  between  35
and  79 years  (mean  60.6  ±  12  years).  The  frequency  of hematoma  formation  was  signiﬁcantly  higher
(p  <  0.001)  in  those  who  used  warfarin  than  in  those  who  did not.  Aspirin  (ASA), clopidogrel,  dual
antiplatelet  therapy  (DAT),  and  bridging  to low-molecular-weight  heparin  (LMWH)  did  not  increase  the
risk  of  hematoma  formation  (p >  0.05). Eleven  pocket  revisions  for hematoma  evacuation  were  needed
in  9 patients  (1.6%),  six  of whom  were on warfarin  therapy  (p >  0.05).  Co-morbidities  were  similar  in
patients  with  and  without  hematoma  (p  > 0.05).
Conclusion: The  frequency  of hematoma  is  within  acceptable  ranges  after  pacemaker  placement.  The use of
warfarin  seriously  increases  the risk  of hematoma.  Bridging  to LMWH  safely  prevents  thromboembolism.
3  Jap© 201
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Pocket hematoma is a common complication following device
mplantation accounting for 14–17% of all reoperations [1,2].
spirin and/or clopidogrel use are increasing due to the rising inci-
ence of coronary and peripheral artery diseases. Warfarin use is
ncreasing due to the high frequency of prosthetic valve or atrial
brillation. The risk of pocket hematoma is between 12% and 23%
n patients on oral anticoagulation therapy who are bridged to
ntravenous heparin [3,4]. For comparison, the rate of hematoma
ormation is approximately 2% in patients who  are not receiving
ny anticoagulation and 4% among patients who  have interrup-
ion of oral anticoagulation without bridging [4]. Many risk factors
nd controversial reports for a hematoma were declared in the
iterature. We  aimed to evaluate the effect of antiplatelets and
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anticoagulants on hematoma formation complicating pacemaker
placement.
Methods
Patients
We reviewed all cases admitted or discharged from our institu-
tion between January 2008 and June 2009 for whom a pacemaker
was implanted. In addition, beginning in June 2009, we  prospec-
tively collected data from all patients admitted to our institution,
for whom a pacemaker was placed. General risk factors such as age
and sex, and clinical risk factors such as diabetes mellitus, hyper-
tension, and coronary/peripheral artery disease were evaluated for
whether they predicted the risk of hematoma. Collection and anal-
yses of data were authorized by the ethics commitee of the hospital.Device implant procedures
The  cardiac device implantations or exchanges were performed
according to the standard technique described in the literature
vier Ltd. All rights reserved.
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Table 1
Clinical features of pacemaker implanted patients owing to the hematoma
formation.
Characteristics Hematoma formation
(+) Percent (n = 20) (−) Percent (n = 554)
Sex M:F  55%:45% (11:9) 49%:51% (271:283)
Age  Mean 60.6 ± 12 years Mean 68 ± 15.6 years
Hypertension 75% (15) 67% (372)
Diabetes mellitus 45% (9) 30% (167)
Chronic renal failure 0% (0) 7% (43)
Coronary artery disease 40% (8) 43% (239)
The important ﬁndings of our report are: warfarin therapy
signiﬁcantly increases the risk of hematoma after pacemaker
placement; LMWH  bridging is safe for preventing ischemic com-
plications in high-risk warfarin-interrupted patients.
Table 2
Therapeutic characteristics of pacemaker implanted patients according to the for-
mation of the hematoma.
Medications Hematoma formation
(+)
Percent (n = 20)
(−)
Percent (n = 554)
Aspirin 15% (3) 35%  (193)
Clopidogrel 10% (2) 6.3% (35)28 K.S. Özcan et al. / Journal o
5–7]. In all new implants, venous access was achieved with a
rst rib approach under ﬂuoroscopic guidance to the extra-thoracic
ortion of the subclavian vein. No added precautions or differences
n techniques were performed for patients on anticoagulation com-
ared with non-anticoagulated patients [8,9].
anagement
According to our institutional protocol, we did not discontinue
spirin (ASA), clopidogrel, or dual antiplatelet therapy (DAT) before
he implantation. Warfarin was routinely discontinued before the
rocedure and the operation was performed when prothrombin
ime international normalized ratio (INR) decreased below the
alue of 1.4. Low-molecular-weight heparin (LMWH) bridging was
erformed twice a day (BID) to patients with prosthetic valves. It
as discontinued 12 h before the procedure and restarted 24 h after
he procedure.
Post-implantation, the electrode position was conﬁrmed by
nalyzing the intra-cardiac electrocardiogram, evaluating pac-
ng thresholds, and by chest X-ray. Pacemaker parameters were
ecorded on the day of discharge. Once discharged from hospital,
atients were followed up at a dedicated pacemaker clinic after
our to six weeks.
utcomes
Hematoma was deﬁned as a swelling of pacemaker pocket
ith or without tenderness and pain. Pacemaker pocket swellings
ithout pain and tenderness were followed conservatively. The
ematomas causing a pain and/or tenderness and that were
ncreasing in size were evacuated. Cold and compression therapy
as applied for those who did not require drainage.
tatistical analysis
Categorical measures were summarized by using counts and
ercentages; continuous variables were summarized by using
ither means with standard deviations or medians with an inter-
uartile range, depending on data skew. Univariate comparison
etween continuous variables was performed with the Student T
est or Mann–Whitney U test, and for categorical data, comparison
as performed with the Chi-square test or Fisher exact test. Logis-
ic analysis was applied for multivariate analysis. A p-value <0.05
as considered statistically signiﬁcant. All statistical studies were
arried out using NCSS (Number Cruncher Statistical System) 2007
nd PASS 2008 Statistical Software Program (Kaysville, UT, USA).
esults
aseline  characteristics
A  total of 574 patients (282 male) underwent a perma-
ent pacemaker implantation. The average age was 67 years.
orty eight out of 574 patients had prosthetic valve/s. Patients
ith hematoma were signiﬁcantly younger than patients with-
ut hematoma (p = 0.037). Clinical features such as hypertension,
iabetes mellitus, chronic renal failure, coronary/peripheral artery
iseases, and cerebrovascular accident were similar in patients
ith and without hematoma (p > 0.05). Moreover, the frequency
f placement of prosthetic valve/s was not signiﬁcantly different
ithin the two groups (p = 0.287) (Table 1). Pacing was  DDD(R) or
VI(R) in 83.8% and 16.2% of cases, respectively.Peripheral artery disease 5% (1) 10.1% (56)
Cerebrovascular accident 0% (0) 3.4% (19)
Prosthetic valve 15% (3) 8.1% (45)
Periprocedural antiplatelet or anticoagulation therapy
One hundred ninety six patients (34.1% of all pacemaker
implanted patients) were on ASA only (122.4 ± 13.7 mg), 37
patients (6.4%) were on clopidogrel only (75 mg), and 24 patients
(4.2%) were on DAT (132 mg  of ASA and 75 mg of clopidogrel). Fifty
nine out of 574 patients (10.3%) were on warfarin therapy (Table 2).
By multivariate analysis warfarin was  the only therapy that signif-
icantly increased the risk of hematoma formation (p < 0.001).
The practice during the study period was to discontinue warfarin
3–4 days before device implantation and then reinitiate it 1–2 days
after the procedure. The median INR among these patients at time
of implant was 1.3 (1.1–1.4); 1.31 in the hematoma group and 1.28
in the group without hematoma.
Forty  eight patients with prosthetic valve/s and one patient with
ischemic stroke, who were on warfarin, were bridged to LMWH BID
until the evening before the procedure (Table 2). The LMWH  was
restarted the next morning after the procedure and continued BID
until the INR achieved ≥1.8. Warfarin was  usually restarted 30–36 h
after the procedure.
Outcomes
Twenty  patients (3.6% of all patients, 9 women) experienced
hematoma formation. Of these, 9 patients (1.6% of all patients)
required 11 surgical evacuations for the hematoma. The median
time from the operation to the formation of hematoma was 5 days
(2–7 days). The effect of anticoagulants on the rate of hematoma
evacuation is given in Table 3. Warfarin and LMWH  bridging ther-
apies did not increase the rate of hematoma drainage in patients
with hematoma owing to the pacemaker implantation (p > 0.05).
DiscussionDAT 5% (1) 4.1% (23)
Warfarin 60% (12) 8.5% (47)
LMWH  bridging 15% (3) 8.3% (46)
DAT, dual antiplatelet therapy; LMWH,  low-molecular-weight heparin.
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Table  3
The  effect of anticoagulant therapy on the evacuation of hematoma in patients with
pacemaker-related hematoma.
Anticoagulant therapy Hematoma evacuation
Yes; n (%)
(n  = 9)
No;  n (%)
(n  = 11)
Warfarin
(+) 6 (67%) 6 (55%)
(−) 3 (33%) 5 (45%)
LMWH  bridging
(+)  1 (11%) 2 (18%)
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[(−) 8 (89%) 9 (82%)
MWH,  low-molecular-weight heparin.
linical features
In  our population, patients with hematoma were signiﬁcantly
ounger than those without hematoma. Hypertension, diabetes
ellitus, and prosthetic valve/s were common in younger patients
Table 1). Although, these ﬁndings were all statistically insignif-
cant, this may  explain that younger patients who required a
acemaker could have more co-morbidities than older patients
ith bradyarrhythmia commonly attributable to the degeneration
f the conductive pathway. To our knowledge, there is no report
eclaring that younger patients are more prone to hematoma than
lderly.
ntiplatelets’ effect on hematoma formation
Prolonged DAT is recommended for all patients after stent
mplantation and the majority of patients presenting with acute
oronary syndromes. The number of patients that are receiving
AT at the time of cardiac device implantation is increasing [10].
n the literature, there are some reports declaring increased rate
f bleeding complications in patients receiving clopidogrel or DAT
ho undergo cardiac device implantation [11,12]. Contrary to
hese reports, in our series clopidogrel or DAT did not signiﬁ-
antly increase the risk of hematoma formation. Moreover, in one
rospective, two-center registry the rate of hematoma was  not
ncreased by DAT [10]. The main reason for the discrepancy in
he DAT effect on the rate of hematoma might be the absence of
acemaker pocket hematoma guidelines. Hence, the deﬁnition of
ematoma may  be different in different clinics and reports.
In  our cohort, ASA use was more common in patients without
ematoma than with hematoma. Although this was  statistically
nsigniﬁcant, it may  imply that ASA usage is not a predictor of a
ematoma.
nticoagulants’ effect on hematoma formation
Warfarin users were at increased risk for hematoma formation
fter the placement of pacemaker. Giudici et al. continued anti-
oagulation with warfarin in 470 patients with INRs ≥1.5 at the
ime of the procedure (mean INR 2.6 ± 1.0, range 1.5–7.5). Only
ine hematomas occurred and of these just two  patients underwent
ocket revision [13]. Amara et al. reported similar ﬁndings with the
ontinuation of warfarin during the cardiac device placement: INR
as >2 and 3 out of 43 patients experienced pocket hematoma (NS
ompared to non-anticoagulated patients) [14]. Our practice was
o routinely discontinue warfarin before the procedure that is why
e cannot make any suggestion about the safety of periprocedural
ontinuation of warfarin therapy. All of our patients experienced
 hematoma until the seventh day after the operation. Thus, the
uthors thought that limited arm movement and periodical com-
ression on pacemaker site during the ﬁrst week of operation may
educe the rate of hematoma formation.
[
[iology 62 (2013) 127–130 129
In  the literature, there are many reports about the risk of the
bridging to intravenous heparin or LMWH  [10,15,16]. Our ﬁndings
were in contrast to these reports and LMWH  bridging does not
increase the rate of hematoma formation. Moreover, this approach
safely protects our patients from potential ischemic complications:
none of the pacemaker implanted patients experienced an ischemic
stroke or systemic thromboembolism. Although there were few
patients, bridging to LMWH  had no signiﬁcant effect on the rate
of the drainage of hematoma.
Limitations
Data  from half our cohort were collected retrospectively, and
thus bear the inherent limitations of such studies. Because the def-
inition of cardiac device pocket site hematoma is not standardized
it could be over- or under-estimated in our population, and affect
the proportion and clinical signiﬁcance of the effects of antiplatelets
and/or anticoagulants on hematoma formation.
Conclusion
A cardiac device implantation-related hematoma rate of 3.6%
was demonstrated. The major risk factor for hematoma formation
is the usage of warfarin. Bridging to LMWH  safely protects high-risk
patients from systemic thromboembolism.
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